Hormonal characteristics of androgen status and their relationship with the anthropometric and metabolic parameter in men depending on the severity of hypertension

Background. According to the literature data, long-term and poorly controlled hypertension (HTN) leads to target organs damage, and in some cases, to the development of associated diseases, the severity of which in men may be partly due to the characteristics of the androgenic status.

The aim: to reveal the features of hormonal indicators of androgen status and their relationship with the anthropometric and metabolic characteristics of the therapeutic clinic male patients, depending on the severity of HTN.

Materials and methods. 296 men aged 59,0 [54,0; 65,0] years with confirmed HTN were examined. All study participants in the morning on an empty stomach underwent anthropometry, determination of metabolic and androgenic status, and assessment of comorbid burden. Depending on the severity of hypertension, all patients were divided into two groups (G): G1 (n = 134) – patients with hypertension without a history of coronary artery disease or stroke; G2 (n = 162) – patients with hypertension with a history of ischemic heart disease (IHD) and/or stroke.

Results. In male patients of G2 with severe HTN, a decrease in the levels of free testosterone (FT) and, to a greater extent, dehydroepiandrosterone sulfate (DHEA-S), as well as total cholesterol, high and low density lipoproteins, was revealed. The correlation analysis performed revealed statistically significant negative correlations between the levels of total testosterone (TT) and FT with body mass index, the value of the ratio of waist circumference to hips, only the level of FT – with the presence of IHD, chronic heart failure (CHF), disorders of carbohydrate metabolism and abdominal type of fat distribution, and the level of DHEA-S – with the presence of IHD and CHF.

Conclusion. A decrease in FT and DHEA-S is associated with early progression of atherosclerosis and the risk of developing HTN-associated cardiovascular events, which can aggravate the course of HTN.

1. Balanova YA, Kontsevaya AV, Myrzamatova AO, Mukaneeva DK, Khudyakov MB, Drapkina OM. Economic burden of hypertension in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2020; 16(3): 415-423. (In Russ.). doi: 10.20996/18196446-2020-05-03

2. Denisova AR, Solntseva TD, Sivakova OA, Chazova IE. Uncontrolled arterial hypertension: Main causes, features of pathogenesis and approaches to treatment. Systemic Hypertension. 2021; 18(1): 13-18. (In Russ.). doi: 10.26442/2075082X.2021.1.200724

3. Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol. 2018; 14(3): 185-201. doi: 10.1038/nrneph.2017.189

4. Lebedeva NB, Hoffman VV. Age-related hypogonadism and cardiovascular disease risk. Fundamental and Clinical Medicine. 2020; 5(2): 60-66. (In Russ.). doi: 10.23946/2500-0764-2020-5-2-60-66

5. Zhang J, Li X, Cai Z, Li H, Yang B. Association between testosterone with type 2 diabetes in adult males, a meta-analysis and trial sequential analysis. Aging Male. 2019; 23(5): 607-618. doi: 10.1080/13685538.2018.1557139

6. Tyuzikov IA. Dehydroepiandrosterone in men: a potential physiological effects from the standpoint of evidence-based medicine. Effective Pharmacotherapy. 2020; 16(20): 44-51. (In Russ.). doi: 10.33978/2307-3586-2020-16-20-44-51

7. Park M, Kim S, Won Y. Relationship between testosterone deficiency and the cardiovascular risk factors, diabetes and hypertension. J Mens Health. 2020; 16(4): 97-109. doi: 10.31083/jomh.v16i4.328

8. Bianchi VE.Testosterone, myocardial function, and mortality. Heart Fail Rev. 2018; 23(5): 773-788. doi: 10.1007/s10741-018-9721-0

9. Popov PS, Kournikova IA, Torshin VI, Malyutina NN. State of lipid metabolism in patients receiving androgen replacement therapy. Perm Medical Journal. 2020; 37(5): 20-26. (In Russ.). doi: 10.17816/pmj37520-26

10. Zelenina TA, Salukhov VV, Zemlyanoy AB, Chebykina OE. Testosterone replacement therapy in men with type 2 diabetes mellitus and neuropathy. Farmateka. 2021; 28(4): 55-61. (In Russ.). doi: 10.18565/pharmateca.2021.4.55-60

11. Ghadimi R, Khalilipour A, Malekian N, Esmaili H, Hosseini SR, Bayani M. Serum testosterone and metabolic syndrome in old-aged males: preliminary findings of the AHAP cohort study. Rom JDiabetes Nutr Metab Dis. 2020; 27(3): 245-250. doi: 10.46389/rjd-2020-1036

12. Lebedeva NB, Hoffman VV. Current understanding of the role of age-related hypogonadism in the development of cardiovascular diseases. Terapevticheskii arkhiv. 2020; 93(1): 79-83. (In Russ.). doi: 10.26442/00403660.2021.01.200597

13. Bavishi A, Patel RB. Addressing comorbidities in heart failure: Hypertension, atrial fibrillation, and diabetes. Heart Fail Clin. 2020; 16(4): 441-456. doi: 10.1016/j.hfc.2020.06.005

14. Xu X, Wang L, Luo D, Zhang M, Chen S, Wang Y, et al. Effect of testosterone synthesis and conversion on serum testosterone levels in obese men. Horm Metab Res. 2018; 50(09): 661-670. doi: 10.1055/a-0658-7712

15. Pinkhasov BB, Selyatitskaya VG, Karapetyan AR, Astrakhantseva EL. Metabolic syndrome in men and women with upper or lower types of body fat distribution. Health. 2012; 4(12A): 13811389. doi: 10.4236/health.2012.412A200

16. Mustafina SV, Malyutina SK, Rymar OD, Shcherbakova LV, Bobak M, Voevoda MI. The epidemiology of obesity and the development of disorders of glucose metabolism according to a prospective study in Siberia. Obesity and Metabolism. 2015; 12(4): 24-28. (In Russ.). doi: 10.14341/omet2015424-28

17. Mendoza MF, Kachur SM, Lavie CJ. Hypertension in obesity. Curr Opin Cardiol. 2020; 35(4): 389-396. doi: 10.1097/HCO.0000000000000749

18. Ke C, Zhu X, Zhang Y, Shen Y. Metabolomic characterization of hypertension and dyslipidemia. Metabolomics. 2018; 14(9): 117. doi: 10.1007/s11306-018-1408-y

19. Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the strong heart study. Diabetes care. 2017; 40(4): 529-537. doi: 10.2337/dc16-1958

20. Yildiz M, Oktay AA, Stewart MH, Milani RV, Ventura HO, Lavie CJ. Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis. 2020; 63(1): 10-21. doi: 10.1016/j.pcad.2019.11.009

21. Slivnick J, Lampert BC. Hypertension and heart failure. Heart Fail Clin. 2019; 15(4): 531-541. doi: 10.1016/j.hfc.2019.06.007

22. Dzeshka MS, Shantsila A, Shantsila E, Lip GY. Atrial fibrillation and hypertension. Hypertension. 2017; 70(5): 854-861. doi: 10.1161/HYPERTENSIONAHA.117.08934

23. Selyatitskaya VG, Epanchintseva EA, Novikova EG, Shilina NI, Pinkhasov BB. Hormonal characteristics of androgen status in males of different age groups. Advances in Gerontology. 2020; 10(3): 210-214. doi: 10.1134/S2079057020030169

24. Salama N, Blgozah S. Serum estradiol levels in infertile men with non-obstructive azoospermia. Ther Adv Reprod Health. 2020; 14: 2633494120928342. doi: 10.1177/2633494120928342

25. Van Hemelrijck M, Sollie S, Nelson WG, Yager JD, Kanarek NF, Dobs A, et al. Selenium and sex steroid hormones in a US nationally representative sample of men: A role for the link between selenium and estradiol in prostate carcinogenesis? Cancer Epidemiol Biomarkers Prev. 2019; 28(3): 578-583. doi: 10.1158/10559965.EPI-18-0520

26. Bellastella G, Menafra D, Puliani G, Colao A, Savastano S. How much does obesity affect the male reproductive function? Int JObes Suppl. 2019; 9(1): 50-64. doi: 10.1038/s41367-019-0008-2

27. Dedov II, Mokrysheva NG, Melnichenko GA, Rozhivanov RV, Kamalov AA, Mkrtumyan AM, et al. Draft of Russian clinical practice guidelines“Male hypogonadism”. Obesityand Metabolism. 2021; 18(4): 496-507. (In Russ.). doi: 10.14341/omet12817

28. Tereshchenko SN, Galyavich AS, Uskach TM, Ageev FT, Arutyunov GP, Begrambekova YuL. 2020 Clinical practice guidelines for chronic heart failure. Russian Journal of Cardiology. 2020; 25(11): 311-374. (In Russ.). doi: 10.15829/1560-4071-2020-4083

29. Dedov II, Shestakova MV, Mayorov AY, Shamkhalova MS, Sukhareva OYu, Galstyan GR, et al. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020; 23(2S): 4-102. (In Russ.). doi: 10.14341/DM12507

30. Mannella P, Simoncini T, Caretto M, Genazzani AR. Dehydroepiandrosterone and cardiovascular disease. Vitam Horm. 2018; 108: 333-353. doi: 10.1016/bs.vh.2018.05.001

31. Yoshida S, Aihara KI, Azuma H, Uemoto R, SumitomoUeda Y, Yagi S, et al. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis. 2010; 212(1): 310-315. doi: 10.1016/j.atherosclerosis.2010.05.011

32. Wang F, He Y, Santos HO, Sathian B, Price JC, Diao J. The effects of dehydroepiandrosterone (DHEA) supplementation on body composition and blood pressure: A meta-analysis of randomized clinical trials. Steroids. 2020; 163: 108710. doi: 10.1016/j.steroids.2020.108710

33. Sahu P, Gidwani B, Dhongade HJ. Pharmacological activities of dehydroepiandrosterone: A review. Steroids. 2020; 153: 108507. doi: 10.1016/j.steroids.2019.108507